A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2011
05/26/2011	WO2011063140A2 Implantable bone graft materials
05/26/2011	WO2011063115A1 Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
05/26/2011	WO2011063102A1 Apremilast for the treatment of sarcoidosis
05/26/2011	WO2011063076A1 Methods of treating hepatitis c virus with oxoacetamide compounds
05/26/2011	WO2011063048A2 Urinary triaosylceramide (gb3) as a marker of cardiac disease
05/26/2011	WO2011063001A1 Niacin prodrugs and deuterated versions thereof
05/26/2011	WO2011062984A1 Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
05/26/2011	WO2011062964A1 Compounds and methods for altering lifespan of eukaryotic organisms
05/26/2011	WO2011062955A2 Compounds for modulating tlr2
05/26/2011	WO2011062939A1 Methods and compositions for treating solid tumors and other malignancies
05/26/2011	WO2011062930A1 Combination
05/26/2011	WO2011062927A1 Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
05/26/2011	WO2011062906A2 Treatment of atrial fibrillation
05/26/2011	WO2011062903A2 Slow infusion of sulcardine and its salts
05/26/2011	WO2011062889A1 Pyrimidine ether derivatives and methods of use thereof
05/26/2011	WO2011062885A1 Fused bicyclic pyrimidine derivatives and methods of use thereof
05/26/2011	WO2011062864A2 Inhibitors of nox enzymes and methods of use thereof
05/26/2011	WO2011062853A1 Quinolizidinone carboxamide m1 receptor positive allosteric modulators
05/26/2011	WO2011062777A1 Methods and compositions for the treatment of psychotic disorders through the identification of the sult4a1-1 haplotype
05/26/2011	WO2011062766A2 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
05/26/2011	WO2011062765A2 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
05/26/2011	WO2011062640A1 Compounds as l-cystine crystallization inhibitors and uses thereof
05/26/2011	WO2011062628A1 Methods and compositions for modulation of t cells via the kynurenine pathway
05/26/2011	WO2011062614A1 Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
05/26/2011	WO2011062592A2 Ds-1/la vie
05/26/2011	WO2011062561A1 The isolation and characterisation of heparan sulphates and their use in pharmaceutical compositions, methods of treatment and stem cell culture media suitable for conditions associated with bone repair.
05/26/2011	WO2011062550A1 Benzoimidazole compounds and uses thereof
05/26/2011	WO2011062503A1 Parenteral formulations of gemcitabine derivatives
05/26/2011	WO2011062458A2 Composition containing homoisoflavanone as active ingredient for preventing and treating obesity or metabolic syndrome
05/26/2011	WO2011062437A2 Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
05/26/2011	WO2011062372A2 2, 4, 7 -substituted thieno [3, 2 -d] pyrimidine compounds as protein kinase inhibitors
05/26/2011	WO2011062284A1 A cycloalkane derivative
05/26/2011	WO2011062253A1 Novel fused pyrimidine derivative
05/26/2011	WO2011062194A1 Aminopyridine derivative
05/26/2011	WO2011061932A1 Ceramide and collagen synthesis promoter and collagen saccharification inhibitor
05/26/2011	WO2011061760A1 Novel antithrombotic agents
05/26/2011	WO2011061754A1 A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof
05/26/2011	WO2011061751A1 BICYCLIC COMPOUNDS AS α4β2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
05/26/2011	WO2011061748A1 Rifaximin premix
05/26/2011	WO2011061744A2 Novel arylated camphenes, processes for their preparation and uses thereof
05/26/2011	WO2011061743A1 Metadoxine and derivatives thereof for use in the treatment of inflammation and immune-related disorders
05/26/2011	WO2011061679A1 Imidazo-pyrazoles as gpr119 inhibitors
05/26/2011	WO2011061667A1 Use of macrocyclic lactone derivatives for the treatment of inflammatory disorders
05/26/2011	WO2011061666A1 Macrocyclic lactone derivatives for the treatment of cancer
05/26/2011	WO2011061622A1 Compositions for treating centrally mediated nausea and vomiting
05/26/2011	WO2011061616A2 Extended release compositions containing tolterodine and process for preparing the same
05/26/2011	WO2011061615A1 Polysaccharide / bmp complexes which are soluble at physiological ph
05/26/2011	WO2011061613A1 Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
05/26/2011	WO2011061611A1 Process for the preparation of form b of lenalidomide
05/26/2011	WO2011061610A2 Processes for preparation of polymorphic forms of lacosamide
05/26/2011	WO2011061590A1 Novel carboxamide derivatives as hiv inhibitors
05/26/2011	WO2011061554A2 Pharmaceutical composition for the treatment of bladder disorders
05/26/2011	WO2011061545A1 Hplc method for analyzing vorinostat
05/26/2011	WO2011061527A1 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
05/26/2011	WO2011061519A2 Topical foam composition
05/26/2011	WO2011061516A2 Topical foam composition
05/26/2011	WO2011061498A2 Inhalation solutions
05/26/2011	WO2011061469A1 Indazole derivatives and their use for blockading voltage dependent sodium channels
05/26/2011	WO2011061458A1 Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
05/26/2011	WO2011061340A1 Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity
05/26/2011	WO2011061332A1 Pharmaceutical composition comprising propofol
05/26/2011	WO2011061330A2 Use of physiological cooling active ingredients, and agents containing such active ingredients
05/26/2011	WO2011061318A1 Heterocylic compounds as antagonists of the orexin receptors
05/26/2011	WO2011061303A1 Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
05/26/2011	WO2011061302A1 Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv)
05/26/2011	WO2011061298A1 Use of prostaglandins f2alpha and analogues for the healing of corneal and conjunctival lesions
05/26/2011	WO2011061277A1 Amino aryl acetamides and their use in the treatment of malaria
05/26/2011	WO2011061271A1 Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
05/26/2011	WO2011061252A2 Combination therapy for treating or preventing an inflammatory skin disorder
05/26/2011	WO2011061243A1 Heterocyclic antiviral compounds
05/26/2011	WO2011061237A1 Antimicrobial compositions containing free fatty acids
05/26/2011	WO2011061222A1 Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
05/26/2011	WO2011061214A1 Novel heterocyclic acrylamides and their use as pharmaceuticals
05/26/2011	WO2011061168A1 Aryl-pyridine derivatives as aldosterone synthase inhibitors
05/26/2011	WO2011061157A1 Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
05/26/2011	WO2011061155A1 Antifungal formulations and their use
05/26/2011	WO2011061154A1 Iodine-labeled homoglutamic acid and glutamic acid derivatives
05/26/2011	WO2011061139A1 Substituted pyrrolidine-2-carboxamides
05/26/2011	WO2011061110A1 Fluorinated oxa or thia heteroarylalkylsulfide derivatives for combating invertebrate pests
05/26/2011	WO2011060976A1 Tryptamine-derived compounds as antibacterial agents
05/26/2011	WO2011060962A1 Salts of duloxetine and nsaids for the treatment of pain
05/26/2011	WO2011060945A2 Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
05/26/2011	WO2011060873A1 Quinazoline derivatives
05/26/2011	WO2011060746A1 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
05/26/2011	WO2011060634A1 23-hydroxy-betulinic acid derivatives, preparation methods and uses thereof
05/26/2011	WO2011060555A1 Soluble physiological chitosan formulations combined with platelet-rich plasma (prp) for tissue repair
05/26/2011	WO2011060553A1 Formulation and method for rapid preparation of isotonic and cytocompatible chitosan solutions without inducing chitosan precipitation
05/26/2011	WO2011060537A1 Predictive markers for taxane responsiveness and methods of use thereof
05/26/2011	WO2011060513A1 PHARMACEUTICAL COMPOSITION COMPRISING CINCHONAINS Ia AND Ib, PROCESS FOR PREPARING AN EPIMERIC MIXTURE OF CINCHONAINS Ia AND Ib, USE AND METHOD FOR REVERTING/COMBATING VENTRICULAR FIBRILLATION
05/26/2011	WO2011060492A1 Combination for treating metabolic disorders
05/26/2011	WO2011042797A4 Pyrazole derivatives as modulators of calcium release -activated calcium channel
05/26/2011	WO2011041710A3 Docosahexaenoic acid gel caps
05/26/2011	WO2011041609A3 Topical formulations
05/26/2011	WO2011041584A3 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
05/26/2011	WO2011041300A4 Reduced-odor polyol composition and method of producing same
05/26/2011	WO2011039388A3 3-indazolyl ether family with cannabinoid and/or cholinergic properties
05/26/2011	WO2011039367A3 Pharmaceutical compositions comprising bi-1356 and metformin
05/26/2011	WO2011039308A3 Gluten-free foodstuff
05/26/2011	WO2011038924A3 Proteasome inhibitors for treating cancer
05/26/2011	WO2011036677A3 Sustained release composition of ranolazine

1 ... 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 ... 7860